Desired vancomycin trough concentration to achieve an AUC0‐24/MIC ≥400 in Chinese children with complicated infectious diseases

A vancomycin steady‐state trough concentration (Cmin) of 15‐20 mg/L is recommended for achieving a ratio of the 24‐hour area under the curve to the minimum inhibitory concentration (AUC0‐24/MIC) of ≥400 in adults. Since few paediatric data are available, our objectives were to (a) measure the pharmacokinetic indices of vancomycin and (b) determine the correlation between Cmin and AUC0‐24/MIC in paediatric patients. Population‐based pharmacokinetic modelling was performed for paediatric patients to estimate the individual parameters. The relationship between Cmin and the calculated AUC0‐24/MIC was explored using linear regression and a probabilistic framework. A sensitivity analysis was also conducted using Monte Carlo simulations. Body‐weight significantly influenced the pharmacokinetics of vancomycin. Based on real data and simulations, Cmin ranges of 5.0‐5.9 and 9.0‐12.9 mg/L were associated with AUC0‐24/MIC ≥400 for MIC values of ≤0.5 and ≤1 mg/L, respectively. Vancomycin regimens of 10 and 15 mg/kg every 6 hours achieved a Cmin of 5.0‐5.9 mg/L and AUC0‐24/MIC ≥400 in >90% of the children when MIC was ≤0.5 mg/L. At a MIC of ≤1 mg/L, vancomycin at 15 mg/kg every 6 hours achieved Cmin of 9.0‐12.9 mg/L and AUC0‐24/MIC ≥400 in 2.0‐ and 1.6‐fold as many children compared to a dose of 10 mg/kg every 6 hours, respectively. Vancomycin Cmin values of 5.0‐12.9 mg/L were strongly predictive of achieving AUC0‐24/MIC ≥400, and rational dosing regimens of 10‐15 mg/kg q6h were required in paediatric patients, depending on the pathogen.

[1]  Yuzhu Dong,et al.  Paediatric acute kidney injury induced by vancomycin monotherapy versus combined vancomycin and meropenem , 2019, Journal of clinical pharmacy and therapeutics.

[2]  X. Liang,et al.  A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Lykkesfeldt,et al.  Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. , 2018, Basic & clinical pharmacology & toxicology.

[4]  R. Cohen,et al.  Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice. , 2017, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[5]  W. Lu,et al.  Population pharmacokinetics of vancomycin in Chinese pediatric patients
. , 2017, International journal of clinical pharmacology and therapeutics.

[6]  E. Heil,et al.  Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population. , 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[7]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[8]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  P. Gao,et al.  Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function , 2016, Journal of clinical pharmacology.

[10]  J. Le,et al.  Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[11]  M. Sharland,et al.  Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. , 2016, The Journal of antimicrobial chemotherapy.

[12]  J. Vallejo,et al.  Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome , 2016, The Pediatric infectious disease journal.

[13]  J. Pachón,et al.  Optimizing the Clinical Use of Vancomycin , 2016, Antimicrobial Agents and Chemotherapy.

[14]  P. G. Choe,et al.  Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. , 2015, International journal of antimicrobial agents.

[15]  A. Widmer,et al.  2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Widmer,et al.  Executive Summary: 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  K. V. Van Meurs,et al.  Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates , 2014, Antimicrobial Agents and Chemotherapy.

[18]  C. Knoderer,et al.  Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children? , 2014, Journal of the Pediatric Infectious Diseases Society.

[19]  Lisa Lubsch,et al.  Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis , 2013, Pharmacotherapy.

[20]  Roger W. Jelliffe,et al.  Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.

[21]  B. Guglielmo,et al.  Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.

[22]  E. Capparelli,et al.  Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.

[23]  K. Neville,et al.  Defining Risk Factors for Red Man Syndrome in Children and Adults , 2012, The Pediatric infectious disease journal.

[24]  R. Kullar,et al.  Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort , 2012, Pharmacotherapy.

[25]  G. Giachetto,et al.  Vancomycin pharmacokinetic–pharmacodynamic parameters to optimize dosage administration in critically ill children , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[26]  L. Benet,et al.  Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations , 2011, Pharmacotherapy.

[27]  Thomas M. English,et al.  Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.

[28]  R. Kullar,et al.  Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  L. Benet,et al.  Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. , 2010, Clinical therapeutics.

[31]  D. Levine,et al.  Therapeutic Monitoring of Vancomycin in Adults , 2009, Pharmacotherapy.

[32]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  PharmD Lynn L. Estes Therapeutic Monitoring of Vancomycin in Adults , 2009 .

[34]  B. Murray,et al.  Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  G. Eliopoulos,et al.  Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. , 2006, The Journal of antimicrobial chemotherapy.

[36]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[37]  P. Ward,et al.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[39]  R. Wrishko,et al.  Vancomycin Pharmacokinetics and Bayesian Estimation in Pediatric Patients , 2000, Therapeutic drug monitoring.

[40]  J. Rotschafer,et al.  The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. , 1996, The Journal of antimicrobial chemotherapy.

[41]  W. Leader,et al.  Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.

[42]  N. Saunders Why monitor peak vancomycin concentrations? , 1994, The Lancet.

[43]  J. Rotschafer,et al.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique , 1993, Antimicrobial Agents and Chemotherapy.

[44]  F. Vaida,et al.  Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. , 2014, Journal of pharmacology & clinical toxicology.

[45]  B. Bruguerolle,et al.  Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.

[46]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[47]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[49]  P. Landais,et al.  [Acute renal failure associated with drugs or iodinated contrast media. Results of a cooperative multicentric study by the Nephrology Society]. , 1986, Nephrologie.

[50]  G. Mccracken,et al.  Pharmacology and efficacy of vancomycin for staphylococcal infections in children. , 1981, Reviews of infectious diseases.